501971730 06/28/2012

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Thomas Harding	06/06/2012
W. Michael Kavanaugh	06/06/2012

RECEIVING PARTY DATA

Name:	Five Prime Therapeutics, Inc.	
Street Address:	Two Corporate Drive	
City:	South San Francisco	
State/Country:	CALIFORNIA	
Postal Code:	94080	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13509068

CORRESPONDENCE DATA

Fax Number: (608)662-1276 Phone: 6086621277

Email: sefilandrinos@casimirjones.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Rebecca B. Scarr

Address Line 1: 2275 Deming Way, Ste 310
Address Line 4: Middleton, WISCONSIN 53562

ATTORNEY DOCKET NUMBER: FPT-32620/US-2/PCT

NAME OF SUBMITTER: Rebecca B. Scarr

Total Attachments: 1

source=2012-06-06_32620US2PCT_Exec-Assign#page1.tif

PATENT REEL: 028458 FRAME: 0835 H &10 00 13

Attorney Docket No.: FPT-32620/US-2/PCT

ASSIGNMENT

WHEREAS, WE, **Thomas Harding** and **W. Michael Kavanaugh**, hereinafter referred to as "ASSIGNORS," have invented certain new and useful improvements as described and set forth in the below-identified application for United States Letters Patent:

Title of Invention:

USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS
CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2

Filing Date:

May 10, 2012

Serial No.:

13/509,068

WHEREAS, Five Prime Therapeutics, Inc., a California corporation having a place of business at Two Corporate Drive, South San Francisco, California, 94080, hereinafter referred to as "ASSIGNEE," is desirous of acquiring the entire right, title and interest in said invention and application and in any Letters Patent which may be granted on the same;

NOW THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNORS have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said ASSIGNEE, and ASSIGNEE's successors and assigns, all right, title and interest in and to said invention, said application for United States Letters Patent, and any Letters Patent which may hereafter be granted on the same in the United States and all countries throughout the world, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, or prolongations or extensions thereof, said interest to be held and enjoyed by said ASSIGNEE as fully and exclusively as it would have been held and enjoyed by said ASSIGNORS had this assignment and transfer not been made, to the full extent and term of any Letters Patent.

ASSIGNORS further agree that ASSIGNORS will, without charge to said ASSIGNEE, but at ASSIGNEE's expense, cooperate with ASSIGNEE in the prosecution of said application and/or applications; execute, verify, acknowledge, and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof; and perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE's successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNORS have hereunto signed ASSIGNORS' names to this Assignment on the date indicated below.

Thomas Harding

RECORDED: 06/28/2012

DATE

6/6/2012

W. Michael Kavanaugh

MTE

PATENT REEL: 028458 FRAME: 0836